EDAP provides company update on Focal One installation in the United States


The company announces salways kuh we Focus 1 facilities during the fourth trimester

LYON, France, January 5, 2022 – EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a world leader in robotic energy-based therapies, today provided an update on the recent investments of Focal One and the launch of treatments to select new customer sites in the United States.

During the company’s third quarter 2021 conference call in November, EDAP announced that it had sold a Focal One device to the University of California, San Diego (UCSD) during the fourth quarter. The sale to UCSD is now Focal One’s third placement in the prestigious UC healthcare system, following previously announced sales to UC San Francisco and UC Irvine.

In addition, the company announces today that additional Focal One installations took place during the fourth quarter in five prestigious academic reference centers and the integrated health network. These include Brigham and Women’s Hospital in Boston, Cedars-Sinai Health System in Los Angeles, Henry Ford Health System in Detroit, Duke University in North Carolina, and Prisma Health in South Carolina.

Marc Oczachowski, Chairman and CEO of EDAP, said: “The strong growth of Focal One programs that we experienced during the fourth quarter of 2021 gives us immense optimism as the new year approaches. It is very encouraging to see such growth in market adoption less than six months after the significant restructuring and investment of our U.S. operations, which included the addition of Ryan Rhodes as the new CEO of EDAP Technomed Inc., our American subsidiary.

Ryan Rhodes, CEO of EDAP US, said: “We enter 2022 with tremendous momentum led by the adoption of Focal One by several top institutions in the fourth quarter that can serve as benchmarks. We continue to assemble and develop a strong sales and service organization in the United States. We believe that focal therapy is becoming a necessary part of any comprehensive prostate oncology program and that Focal One is uniquely positioned to provide robot-controlled, precise, and non-invasive treatment under the direction of urologists.

On EDAP TMS SA

Recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes minimally invasive medical devices for various pathologies using ultrasound technology worldwide. By combining the latest technologies in imaging and treatment modalities in its complete line of robotic HIFU devices, EDAP TMS has introduced the Focal One® in Europe and the United States as the answer to all requirements for ideal ablation of the prostate tissue. With the addition of the ExactVu ™ micro-ultrasound machine, EDAP TMS is now the only company to offer a complete solution from diagnosis to focal treatment of prostate cancer. EDAP TMS also manufactures and distributes other medical equipment, including the Sonolith® i-move lithotripter and lasers for the treatment of urinary stones using extracorporeal shock wave lithotripsy (ESWL). For more information about the Company, please visit http://www.edap-tms.com and us.hifu-prostate.com.

Forward-looking statements

In addition to historical information, this press release contains forward-looking statements. These statements are based on the current expectations of management and are subject to a number of risks and uncertainties, including matters which we do not yet know or do not currently consider to be material, and there can be no assurance that planned events will occur or that the set goals will actually be achieved. Important factors that could cause actual results to differ materially from results anticipated in forward-looking statements include, among others, the clinical condition and market acceptance of our HIFU devices and the continued commercial potential of our device. lithotripsy, as well as the duration and severity of the recent COVID-19 outbreak, including its impacts across all of our businesses on demand for our devices and services. Factors that could cause such a difference may also include, but are not limited to, those described in documents filed by the Company with the Securities and Exchange Commission and in particular, in the sections “Caution Regarding Forward-Looking Information” and “Risk Factors” in the Company’s Annual Report on Form 20-F.

Company contact
Blandine Comfort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
[email protected]

Investor contact
Jean Fraunces
LifeSci Advisors, LLC
212-915-2568
[email protected]

About Irene J. O'Donnell

Check Also

Miniature Tin Man Art Installation Funding: Randy Glysch Raised $35,000 for Privately Funded Project | Community

While village president Randy Glysch recently launched and announced his plans for a public art …